Safety and Efficacy of Zicronapine in Patients With Schizophrenia Safety and Efficacy of Zicronapine in Patients With Schizophrenia - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element Definitions if submitting registration or results information ).Please remove one or more studies before adding more. Safety and Efficacy of Zicronapine in Patients With Schizophrenia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT01295372
Study of the Safety, Tolerability and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record Save this study WarningYou have reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has
Contacts and Locations More Information Brief Summary: The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.Condition or disease Intervention/treatment Phase Schizophrenia Drug: Zicronapine Drug: Olanzapine Phase 2 Detailed Description: Schizophrenia Arm Intervention/treatment Experimental: Zicronapine Drug: Zicronapine5-7mg/day; orally, encapsulated tablets, once dailyOther Name: Lu 31-130 Active Comparator: Olanzapine Drug: Olanzapine10-15mg/day; orally, encapsulated tablets, once dailyOther Name: Zyprexa Outcome Measures Go to Top
Contacts and Locations More Information Brief Summary: The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.Condition or disease Intervention/treatment Phase Schizophrenia Drug: Zicronapine Drug: Placebo Phase 2 Detailed Description: Schizophrenia is a serious and disabling /treatment Experimental: Zicronapine. Study Part A Drug: ZicronapineStudy Part A: 3mg; orally, film-coated tablets, once daily, 8 weeks Other Name: Lu 31-130 Experimental: Zicronapine. Study Part B Drug